Find your path to Dongxing
119 people in our graph share verified history with Dongxing — schools, employers, funds. One of them is your warm intro.
Jesper GromadaunlockedDongxing: together at Novo Nordisk (1998–1999)
×2Dongxing: together at MD Anderson Cancer Center
×3Dongxing: together at Novo Nordisk
×2Dongxing: together at Chinese Academy Of Sciences
About
Dongxing Zha is founder and CEO of Keyway TCR Discovery and co-founder and CEO of Ypsilon Therapeutics, companies focused on TCR-based and TCRm therapeutics for cancer. He has over two decades of experience in immuno-oncology and biologics research and development, with prior scientific leadership roles at MD Anderson Cancer Center and Merck Research Laboratories, where he led discovery programs in bispecifics, TCRs, and cell therapy.
Experience
- Ypsilon TherapeuticsDirector Board of Directorscurrent2022 — present
- Ypsilon TherapeuticsFounder and CEOcurrent2022 — presentHouston, Texas
- Alloy Therapeutics, Inc.CTO, TCR Discovery and Engineering at Alloy Therapeutics | Founder and CEO at Keyway TCR Discovery2021 — 2025Boston, Massachusetts, United States
- MD Anderson Cancer CenterInstitute Head, ORBIT Platform2019 — 2021Greater Houston
- MD Anderson Cancer CenterInstitute Associate Director2017 — 2019Greater Houston
- MD Anderson Cancer CenterInstitute Group Leader2014 — 2017Greater Houston
- MerckResearch Fellow and Group Leader2006 — 2014
- GlycoFiSenior Research Scientist2002 — 2006Lebanon, NH
- Max-Planck-Institut für KohlenforschungPostdoctoral Fellow1999 — 2002
- Novo NordiskResearch Scientist1998 — 1999
- Chinese Academy of SciencesScientist1997 — 1998
Skills & more
Oncology3Pharmaceutics2Drug Discovery32Monoclonal Antibodies18Antibodies34Protein Engineering11yeast surface displayDirected evolutionPreclinical studies1Autoimmune DiseasesSystemic lupus erythematosusPhage display
+12 more
Bispecific antibodiesStandard Molecular BiologyB-cell biologyImmunomodulatoryGlycobiologyProtein expression and yield improvementError-prone PCRDNA library constructionBiomarkersDrug DevelopmentAssay DevelopmentBiochemistryFrom Dongxing's professional profile.
Colleagues at 82VS
Andrei Ramirez-Valdez
Venture Associate at 82VS
Andrew Peterson
Founder / EIR at 82VS
Arthur Suckow
Investor at 82VS
Caitlin Tolman
Chief Operating Officer at 82VS
Colby Jordan
Vice President, Capital Formation at 82VS
Errik Anderson
Board Director at Basecamp Fund
Hemanta Baruah
Founder / EIR at 82VS
June Almenoff
Investor at 82VS
Frequently asked questions
- Who is Dongxing Zha?
- Dongxing Zha is founder and CEO of Keyway TCR Discovery and co-founder and CEO of Ypsilon Therapeutics, companies focused on TCR-based and TCRm therapeutics for cancer. He has over two decades of experience in immuno-oncology and biologics research and development, with prior scientific leadership roles at MD Anderson Cancer Center and Merck Research Laboratories, where he led discovery programs in bispecifics, TCRs, and cell therapy.
- Where does Dongxing Zha work?
- Dongxing Zha is Founder / EIR at 82VS.
- Where did Dongxing Zha go to school?
- Dongxing Zha studied at Huazhong Agricultural University (Doctor of Philosophy - PhD, Microbiology, General).
Shared employers
Also worked at Ypsilon Therapeutics2
Also worked at Alloy Therapeutics, Inc.21
Jesse RobbinsFounder and Investor in AI Developer ToolsUlrik B. NielsenGeneral Partner at Mission BiocapitalChaya PatelPrincipal at Mission BiocapitalErrik AndersonBoard Director at Basecamp FundAlasdair ThongFounding Partner at Selvedge VentureEsra BerkolChief of Staff at Selvedge Venture
+ 15 more
Also worked at MD Anderson Cancer Center28
Evan PunPortfolio Support at 8VCTarek El-SawyVenture Partner at RaivenKevin CyrResearch Associate at Global BioAccess FundAleece HobsonVenture Partner at HX Venture FundAnil ShettyLife Science Committee Chair at Houston Angel NetworkJackson SavageAssociate at Telegraph Hill Partners
+ 22 more
Also worked at Merck153
Anika GuptaInvestor at GV (Google Ventures)Sam BlackmanEntrepreneur in Residence at GV (Google Ventures)Catherine Pearce, DHSc, MBAAdvisor at CincyTechDavid MollerInvestor at Third Rock VenturesAlan EzekowitzInvestor at Third Rock VenturesUri LopatinInvestor at Khosla Ventures
+ 147 more